Table 2.

Prevalence and Adjusted^* Odds ratio for Histological Features in Lifetime non-drinkers and Modest Drinkers

		Life Time Non Drinker	Modest Drinker	Adjusted Summary Odds Ratio (95% Confidence Interval)	p
Steatohepatitis	None	16.3%	22.7%	0.52(0.36 – 0.76)	0.0006
	Borderline	13.9%	24.2%
	Definite	69.8%	53.2%
Macrovesicular Steatosis	5–33%	44.8%	41.7%	1.11(0.79 – 1.55)	0.56
	34–66%	32.9%	35.6%
	>66%	22.2%	22.7%
Microvesicular Steatosis	Absent	86.1%	92.7%	0.57(0.31 – 1.06)	0.57
	Present	13.9%	7.3%
Lobular Inflammation*	<2 foci	52.2%	51.1%	1.09(0.77 – 1.55)	0.63
	2–4 foci	37.3%	36.0%
	>4 foci	10.7%	13.0%
Portal Inflammation	None	9.5%	18.7%	0.69(0.48 – 1.00)	0.052
	mild	64.3%	62.8%
	>mild	26.2%	18.4%
Fibrosis Stage†	0	19.9%	30.0%	0.56(0.41 – 0.78)	0.0005
	1	24.7%	33.6%
	2	22.3%	15.6%
	3	20.3%	14.7%
	4	12.7%	6.1%
Ballooning Degeneration	None	25.8%	37.8%	0.62(0.45 – 0.87)	0.006
	Few	26.2%	26.3%
	Many	48.0%	36.0%
Mallory-Denk bodies	Rare/absent	65.1%	74.9%	0.65(0.43 – 0.97)	0.04
	Many	34.9%	25.1%
Acidophil Bodies	Rare/absent	71.0%	68.3%	1.16(0.79 – 1.72)	0.46
	Many	29.0%	31.7%
Large Lipogranulomas	Absent	57.5%	61.3%	0.73(0.50 – 1.07)	0.11
	Present	42.5%	38.7%
Megamitochondria	Rare/absent	81.7%	87.0%	0.71(0.43 – 1.18)	0.19
	Many	18.3%	13.0%

Multivariate models adjusted for gender, age, race, income, education BMI, recreational and non-recreational physical activity, smoking, total calories per day, percent calories from carbohydrates and percent calories from fat

^*Foci per 200x field

^†Fibrosis stage 0 = none, stage 1 = perisinusoidal or periportal, stage 2 = perisinusoidal and portal / periportal, stage 3 = bridging fibrosis, stage 4 = cirrhosis